Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
|
Device | LIAISON® XL MUREX anti-HBe, LIAISON® XL MUREX Control anti-HBe |
Generic Name | Test, hepatitis b (b core, be antigen, be antibody, b core igm) |
Applicant | DiaSorin Inc. 1951 Northwestern Avenue Stillwater, MN 55082 |
PMA Number | P180049 |
Date Received | 12/19/2018 |
Decision Date | 08/29/2020 |
Product Code |
LOM |
Docket Number | 20M-1822 |
Notice Date | 09/01/2020 |
Advisory Committee |
Microbiology |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the LIAISON® XL MUREX anti-HBe, LIAISON® XL MUREX Control anti-HBe. The LIAISON® XL MUREX Anti-HBe assay is an in vitro chemiluminescent immunoassay (CLIA) for the qualitative detection of total antibodies to hepatitis B e antigen (anti-HBe) in human adult and pediatric (2 to 21 years) serum and plasma (lithium and sodium heparin, sodium citrate and K2 EDTA), including separator tubes, on the LIAISON® XL Analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for hepatitis B (HBV) infection.This assay is not approved for use in screening blood, plasma or tissue donors. The LIAISON® XL MUREX Control Anti-HBe (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the LIAISON® XL MUREX Anti-HBe assay. The performance characteristics of LIAISON® XL MUREX Control Anti-HBe have not been established for any other assays or instrument platforms different from LIAISON® XL Analyzer. |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S008 S009 S007 S013 S016 S010 S002 S003 S004 S005 S006 S011 S015 S017 S014 |
|
|